Table 2.
Characteristics | Number n (%) | TB+n (%) | TB-n (%) | Bivariate analysis |
Multivariate analysis |
||
---|---|---|---|---|---|---|---|
RR [95% CI] | p | RRa [95% CI] | p | ||||
Young age (years) | |||||||
18 - 24 | 62 (17.90) | 41 (66.13) | 18 (29.03) | – | – | – | |
25 - 30 | 284 (82.10) | 31 (10.92) | 255 (89.79) | 18.73 [9.60–36.53] | <0.001 | 1.10 [0.80–1.57] | ** |
Older age (years) | |||||||
31 - 44 | 226 (68.27) | 27 (11.95) | 204 (90.27) | – | – | – | |
45 et plus | 105 (31.73) | 5 (4.76) | 96 (91.43) | 2.54 [0.94–6.80] | 0.057 | – | – |
Sex | |||||||
Male | 192 (28.36) | 26 (13.54) | 166 (86.46) | – | – | – | |
Female | 485 (71.64) | 78 (16.08) | 407 (83.92) | 0.81 [0.50–1.31] | 0.47 | – | – |
CD4 rate | |||||||
< 350 | 535 (79.02) | 92 (17.20) | 443 (82.80) | – | – | ||
≥ 350 | 142 (20.98) | 12 (8.45) | 130 (91.55) | 2.24 [1,19–4.23] | 0.012 | 3.20 [1.81–5.90] | **** |
Clinical stage by WHO | |||||||
I & II | 433 (63.96) | 31 (7.16) | 402 (92.84) | – | – | ||
III & IV | 244 (36.04) | 73 (29.92) | 171 (70.08) | 0.18 [0.11–0.28] | <0.001 | 0.55 [0.40–0.75] | **** |
ARV treatment | |||||||
Before ART | 218 (32.20) | 91 (41.74) | 127 (58.26) | – | – | ||
ART | 459 (67.80) | 13 (2.83) | 446 (97.17) | 24.58 [13.30–45.40] | <0.001 | 7.56 [2.12–26.96] | **** |
Observance | |||||||
Good | 459 (67.80) | 33 (7.04) | 426 (90.83) | – | – | – | |
Medium/Poor | 218 (32.20) | 71 (32.57) | 147 (67.43) | 0.16 [0.10–0,25] | <0,001 | 0,92 [0,62–1,38] | ** |
Capacité fonctionnelle | |||||||
Active | 504 (74,44) | 28 (5,56) | 476 (94,44) | – | – | ||
Grabataire | 173 (25,56) | 76 (43,93) | 97 (56,07) | 0,07 [0,04–0.12] | <0.001 | 0.15 [0.12–0.95] | *** |
RR = Risk Ratio; RRa = Adjusted Risk Ratio; 95% CI= Confidence Interval 95%; p = p-value; **** = p < 0.001; *** = p < 0.05; ** = p > 0.05.